Chronic Pancreatitis (CP) Market Report 2026

Chronic Pancreatitis (CP) Market Overview

• Chronic Pancreatitis (CP) market size has reached to $5.23 billion in 2025 • Expected to grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Increasing Alcohol Consumption Drives Growth Of Chronic Pancreatitis Market • Market Trend: Advancements In Enzyme Replacement Therapy For Exocrine Pancreatic Insufficiency In Chronic Pancreatitis • North America was the largest region in 2025.

What Is Covered Under Chronic Pancreatitis (CP) Market?

Chronic pancreatitis (CP) is a long-lasting, progressive inflammatory condition of the pancreas that causes permanent damage to its structure and function. The disease is marked by persistent inflammation, fibrosis (scarring), and the eventual deterioration of the pancreas's ability to produce digestive enzymes and hormones such as insulin. The main treatment types of chronic pancreatitis (CP) are analgesics, artificial digestive enzymes, protein supplements, steroids, antibiotics, and others. Analgesics are medications designed to relieve pain, a common symptom of chronic pancreatitis. The diagnosis includes computed tomography (CT) scan, magnetic resonance cholangiopancreatography, ultrasound sonography, and others, and the various routes of administration are oral and parenteral. It is used by different end users such as hospitals, home care, and others.

What Is The Chronic Pancreatitis (CP) Market Growth Forecast?

The chronic pancreatitis (cp) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing development of advanced enzyme formulations, rising focus on early-stage intervention, expansion of outpatient treatment models, growing integration of nutrition-based therapies, increasing investment in pancreatic disease research. Major trends in the forecast period include increasing use of enzyme replacement therapies, rising adoption of minimally invasive endoscopic treatments, growing focus on nutritional management, expansion of personalized treatment plans, enhanced emphasis on early diagnosis.

Global Chronic Pancreatitis (CP) Market Segmentation

1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Other Treatments 2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis 3) By Route Of Administration: Oral, Parenteral 4) By End User: Hospitals, Homecare, Other End Users Subsegments: 1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids 2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin 3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein 4) By Other Treatments: Endoscopic Treatment, Surgery

What Is The Driver Of The Chronic Pancreatitis (CP) Market?

The increasing consumption of alcohol is expected to propel the growth of the chronic pancreatitis market going forward. Alcohol consumption refers to the intake of beverages containing ethanol, commonly for recreational, social, or cultural purposes, but it can also lead to dependency or health risks when consumed excessively. The increasing consumption of alcohol is driven by factors such as rising social acceptance, urbanization, changing lifestyles, and stress management practices, especially among younger populations. Alcohol consumption causes chronic pancreatitis by triggering inflammation and damage to pancreatic cells, leading to fibrosis, ductal blockages, and long-term dysfunction due to toxic metabolic byproducts. For instance, in 2025, according to the Priory Group is a UK-based provider of mental health, addiction, and specialist education services, a 2023 survey found that 25% of UK individuals aged 18–24 now abstain from alcohol entirely, highlighting a notable shift toward sobriety among the younger generation. Therefore, the increasing consumption of alcohol is driving the growth of the chronic pancreatitis market.

Key Players In The Global Chronic Pancreatitis (CP) Market

Major companies operating in the chronic pancreatitis (cp) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy's Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech

Global Chronic Pancreatitis (CP) Market Trends and Insights

Major companies operating in the chronic pancreatitis market are focusing on developing technological advancements such as enzyme replacement therapy to address exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Enzyme replacement therapy involves taking oral pancreatic enzymes to aid digestion in patients with insufficient pancreatic function. For instance, in July 2023, First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, announced the results from the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the Yarrowia lipolytica yeast administered as an oral, non-systemic biologic capsule, designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients.

What Are Latest Mergers And Acquisitions In The Chronic Pancreatitis (CP) Market?

In March 2023, CalciMedica Inc. a US-based clinical-stage biopharmaceutical company, merged with Graybug Vision Inc. for an undisclosed amount. This merger, structured as a reverse transaction, allows CalciMedica to enhance its focus on developing therapies for life-threatening inflammatory diseases. Graybug Vision Inc. is a US-based clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory disease, including pancreatitis.

Regional Outlook

North America was the largest region in the chronic pancreatitis (CP) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Pancreatitis (CP) Market?

The chronic pancreatitis market consists of revenues earned by entities by providing services such as diagnostic imaging, endoscopic procedures, pain management, nutritional counseling, and telemedicine services for the diagnosis and management of chronic pancreatitis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pancreatitis market also includes sales of enzyme replacement therapies, pain management drugs, anti-inflammatory treatments, biologics, stem cell therapies, and surgical interventions, as well as diagnostic tools such as imaging and laboratory tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Pancreatitis (CP) Market Report 2026?

The chronic pancreatitis (cp) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pancreatitis (cp) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.